SEC For	m 4															
FORM 4 UNITED			UNITED S	STATES SECURITIES AND EXCHANGE CON Washington, D.C. 20549								SSION		OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				ATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB N Estima	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person <sup>*</sup> Krop Julie					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aquestive Therapeutics, Inc.</u> [ AQST ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 06/22/2022							<ul> <li>Officer (give title Other (specify below)</li> <li>below)</li> </ul>				
30 TECF (Street) WARRE			07059	4.	Line)							int/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting				
(City) (State) (Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Fransactio te onth/Day/\	Execution Dat			Code (Inst	n Disposed			5. Amour Securitie Beneficia Owned F	s Illy ollowing	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
							Code V	Amount	(A) or (D)	Price	rice Reported Transaction (Instr. 3 and				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Purchase)	\$0.7132	06/22/2022		А		25,000		06/22/2023 <sup>(1)</sup>	06/22/2032	Common Stock	25,000	\$0	25,000	)	D	

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 22, 2023, subject to Dr. Krop's continuous service with the Issuer from the grant date through the applicable vesting date.

## Remarks:

## <u>/s/ Lori Braender, as Attorney-</u> <u>In-Fact</u>

06/24/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.